Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lorigerlimab - MacroGenics

Next Previous
Drug Profile

Lorigerlimab - MacroGenics

Alternative Names: AEX1344; EXPASY; MGD-019; PD-1 x CTLA-4 bispecific DART molecule

Latest Information Update: 27 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MacroGenics
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Programmed cell death 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gynaecological cancer; Prostate cancer
  • Phase I/II Solid tumours
  • Discontinued Ovarian cancer

Most Recent Events

  • 13 May 2026 Discontinued - Phase-II for Ovarian cancer (Late-stage disease, Second-line therapy or greater) in USA, South Korea (IV)
  • 13 May 2026 Discontinued - Phase-II for Ovarian cancer (Second-line therapy or greater, Late-stage disease) in Canada (IV)
  • 13 May 2026 Updated adverse events and efficacy data from the phase II LINNET trial in Gynaecological cancer released by MacroGenics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top